JP5466145B2 - 抗増殖性を有する2,6,9−置換プリン誘導体 - Google Patents
抗増殖性を有する2,6,9−置換プリン誘導体 Download PDFInfo
- Publication number
- JP5466145B2 JP5466145B2 JP2010501585A JP2010501585A JP5466145B2 JP 5466145 B2 JP5466145 B2 JP 5466145B2 JP 2010501585 A JP2010501585 A JP 2010501585A JP 2010501585 A JP2010501585 A JP 2010501585A JP 5466145 B2 JP5466145 B2 JP 5466145B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- mmol
- alkyl
- arh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001028 anti-proliverative effect Effects 0.000 title description 8
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title description 7
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 219
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 33
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 32
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000002062 proliferating effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 108090000433 Aurora kinases Proteins 0.000 claims description 7
- 102000003989 Aurora kinases Human genes 0.000 claims description 7
- 102000038624 GSKs Human genes 0.000 claims description 7
- 108091007911 GSKs Proteins 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 108091007914 CDKs Proteins 0.000 claims description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000012875 competitive assay Methods 0.000 claims description 3
- 230000009223 neuronal apoptosis Effects 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 173
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 102
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 73
- 235000019439 ethyl acetate Nutrition 0.000 description 69
- 239000000243 solution Substances 0.000 description 64
- 239000011541 reaction mixture Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000002904 solvent Substances 0.000 description 44
- 239000012300 argon atmosphere Substances 0.000 description 42
- 239000000741 silica gel Substances 0.000 description 42
- 229910002027 silica gel Inorganic materials 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- 239000012267 brine Substances 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 239000003921 oil Substances 0.000 description 33
- 238000003818 flash chromatography Methods 0.000 description 32
- 239000000047 product Substances 0.000 description 32
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 31
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 30
- 239000000758 substrate Substances 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 27
- 101150065749 Churc1 gene Proteins 0.000 description 27
- 102100038239 Protein Churchill Human genes 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 27
- -1 for example Proteins 0.000 description 26
- 239000008346 aqueous phase Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 19
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 19
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 19
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 17
- BKFGLDUWYUYHRF-UHNVWZDZSA-N (2r,3s)-3-aminopentan-2-ol Chemical compound CC[C@H](N)[C@@H](C)O BKFGLDUWYUYHRF-UHNVWZDZSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 101150051438 CYP gene Proteins 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000001267 GSK3 Human genes 0.000 description 11
- 108060006662 GSK3 Proteins 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 11
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 10
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 102000001253 Protein Kinase Human genes 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 108060006633 protein kinase Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 9
- UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 description 9
- 208000010412 Glaucoma Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 7
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 7
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 description 7
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000000021 kinase assay Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 108010056274 polo-like kinase 1 Proteins 0.000 description 7
- 150000003212 purines Chemical class 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 102000016736 Cyclin Human genes 0.000 description 6
- 108050006400 Cyclin Proteins 0.000 description 6
- 102000002554 Cyclin A Human genes 0.000 description 6
- 108010068192 Cyclin A Proteins 0.000 description 6
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 description 6
- 108010001483 Glycogen Synthase Proteins 0.000 description 6
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 6
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 208000002780 macular degeneration Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 210000001585 trabecular meshwork Anatomy 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- 102000003909 Cyclin E Human genes 0.000 description 5
- 108090000257 Cyclin E Proteins 0.000 description 5
- 102000002435 Cyclin T Human genes 0.000 description 5
- 108010068106 Cyclin T Proteins 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 5
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 5
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 5
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 5
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000003793 centrosome Anatomy 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 108010026424 tau Proteins Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CBICPSJSXZLNAC-UHFFFAOYSA-N 2-fluoro-9-propan-2-yl-n-(pyridin-3-ylmethyl)purin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CN=C1 CBICPSJSXZLNAC-UHFFFAOYSA-N 0.000 description 4
- AISKFDFVSSENFX-UHFFFAOYSA-N 6-chloro-2-fluoro-9-propan-2-ylpurine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1Cl AISKFDFVSSENFX-UHFFFAOYSA-N 0.000 description 4
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- CSJUGIJIZSGDQL-QFIPXVFZSA-N (2s)-2-(tritylamino)butan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CO)CC)C1=CC=CC=C1 CSJUGIJIZSGDQL-QFIPXVFZSA-N 0.000 description 3
- JAINUFIMBAQRAD-QFIPXVFZSA-N (2s)-2-(tritylamino)butanal Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C=O)C1=CC=CC=C1 JAINUFIMBAQRAD-QFIPXVFZSA-N 0.000 description 3
- GWSYPURAMKENMH-UHFFFAOYSA-N 3-amino-1,1,1-trifluoropentan-2-ol Chemical compound CCC(N)C(O)C(F)(F)F GWSYPURAMKENMH-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102100031168 CCN family member 2 Human genes 0.000 description 3
- 102000002427 Cyclin B Human genes 0.000 description 3
- 108010068150 Cyclin B Proteins 0.000 description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 3
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000004156 Wnt signaling pathway Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000021953 cytokinesis Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000031877 prophase Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- JXKQPAFSJBFUHW-GFCCVEGCSA-N (2r)-1-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]propan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(NC[C@H](O)C)=NC=1NCC1=CC=CN=C1 JXKQPAFSJBFUHW-GFCCVEGCSA-N 0.000 description 2
- KZXJWVRCUAGBBS-XXBNENTESA-N (2r,3s)-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)[C@@H](C)O)C1=CC=CC=C1 KZXJWVRCUAGBBS-XXBNENTESA-N 0.000 description 2
- RWDGCGHIPSWDTF-SFHVURJKSA-N (2s)-2-(dibenzylamino)butan-1-ol Chemical compound C=1C=CC=CC=1CN([C@H](CO)CC)CC1=CC=CC=C1 RWDGCGHIPSWDTF-SFHVURJKSA-N 0.000 description 2
- QJOKRFSPLJVARG-SFHVURJKSA-N (2s)-2-(dibenzylamino)butanal Chemical compound C=1C=CC=CC=1CN([C@H](C=O)CC)CC1=CC=CC=C1 QJOKRFSPLJVARG-SFHVURJKSA-N 0.000 description 2
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- XCDYFNOQZFHWFO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-[[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]methyl]propan-2-ol Chemical compound N1=C(NCC(O)(C(F)(F)F)C(F)(F)F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CN=C1 XCDYFNOQZFHWFO-UHFFFAOYSA-N 0.000 description 2
- NVRIZFZJZGOIOM-UHFFFAOYSA-N 1,1,1-trifluoro-3-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(NC(CC)C(O)C(F)(F)F)=NC=1NCC1=CC=CN=C1 NVRIZFZJZGOIOM-UHFFFAOYSA-N 0.000 description 2
- XQYCTMGXRKRCSW-UHFFFAOYSA-N 1,1,1-trifluoro-3-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]propan-2-ol Chemical compound N1=C(NCC(O)C(F)(F)F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CN=C1 XQYCTMGXRKRCSW-UHFFFAOYSA-N 0.000 description 2
- UIEPDCACBJEBNK-UHFFFAOYSA-N 1,1,1-trifluoro-3-nitropentan-2-ol Chemical compound CCC([N+]([O-])=O)C(O)C(F)(F)F UIEPDCACBJEBNK-UHFFFAOYSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- TXBLTSMCEXEFMI-UHFFFAOYSA-N 2,6-dimethylpyridine-4-carbonitrile Chemical compound CC1=CC(C#N)=CC(C)=N1 TXBLTSMCEXEFMI-UHFFFAOYSA-N 0.000 description 2
- QGLIOTYTGRWVPT-UHFFFAOYSA-N 2-(aminomethyl)-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound NCC(O)(C(F)(F)F)C(F)(F)F QGLIOTYTGRWVPT-UHFFFAOYSA-N 0.000 description 2
- RETJKTAVEQPNMH-UHFFFAOYSA-N 2-chloro-4,6-dimethylpyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C(Cl)=N1 RETJKTAVEQPNMH-UHFFFAOYSA-N 0.000 description 2
- ZFBCQYWSEOMIJD-UHFFFAOYSA-N 2-fluoro-9-propan-2-yl-n-(pyridin-4-ylmethyl)purin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=NC=C1 ZFBCQYWSEOMIJD-UHFFFAOYSA-N 0.000 description 2
- URZANDAAMCTZFA-UHFFFAOYSA-N 2-fluoro-n-(pyridin-4-ylmethyl)-7h-purin-6-amine Chemical compound C=12N=CNC2=NC(F)=NC=1NCC1=CC=NC=C1 URZANDAAMCTZFA-UHFFFAOYSA-N 0.000 description 2
- CVHPFOWFTVCHBQ-UHFFFAOYSA-N 2-fluoro-n-[(3-fluorophenyl)methyl]-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC(F)=C1 CVHPFOWFTVCHBQ-UHFFFAOYSA-N 0.000 description 2
- FTCZRPSZWQNXNK-UHFFFAOYSA-N 2-fluoro-n-[(3-methylpyridin-2-yl)methyl]-7h-purin-6-amine Chemical compound CC1=CC=CN=C1CNC1=NC(F)=NC2=C1N=CN2 FTCZRPSZWQNXNK-UHFFFAOYSA-N 0.000 description 2
- SZEUTRJDVRFRTP-UHFFFAOYSA-N 2-fluoro-n-[(6-methylpyridin-2-yl)methyl]-7h-purin-6-amine Chemical compound CC1=CC=CC(CNC=2C=3N=CNC=3N=C(F)N=2)=N1 SZEUTRJDVRFRTP-UHFFFAOYSA-N 0.000 description 2
- MAQAXGMFKDQVDP-UHFFFAOYSA-N 2-fluoro-n-[(6-methylpyridin-3-yl)methyl]-7h-purin-6-amine Chemical compound C1=NC(C)=CC=C1CNC1=NC(F)=NC2=C1N=CN2 MAQAXGMFKDQVDP-UHFFFAOYSA-N 0.000 description 2
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 230000012746 DNA damage checkpoint Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 101150055214 cyp1a1 gene Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- DLMICMXXVVMDNV-UHFFFAOYSA-N n,n-di(propan-2-yl)propan-1-amine Chemical compound CCCN(C(C)C)C(C)C DLMICMXXVVMDNV-UHFFFAOYSA-N 0.000 description 2
- AUWPSCRGMXWPKQ-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1CC1 AUWPSCRGMXWPKQ-UHFFFAOYSA-N 0.000 description 2
- SOFVLCDSHOYXME-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-fluoro-7h-purin-6-amine Chemical compound C=12N=CNC2=NC(F)=NC=1NCC1=CC=CC(Cl)=C1 SOFVLCDSHOYXME-UHFFFAOYSA-N 0.000 description 2
- YSPJZEMKUGOFNG-UHFFFAOYSA-N n-[(4,6-dimethylpyridin-3-yl)methyl]-2-fluoro-7h-purin-6-amine Chemical compound C1=NC(C)=CC(C)=C1CNC1=NC(F)=NC2=C1N=CN2 YSPJZEMKUGOFNG-UHFFFAOYSA-N 0.000 description 2
- DEMQDYYIDUWXIF-UHFFFAOYSA-N n-[(4,6-dimethylpyridin-3-yl)methyl]-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CN=C(C)C=C1C DEMQDYYIDUWXIF-UHFFFAOYSA-N 0.000 description 2
- HHXYMJJREISKBU-UHFFFAOYSA-N n-cyclobutyl-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NC1CCC1 HHXYMJJREISKBU-UHFFFAOYSA-N 0.000 description 2
- STYBYKUEWSHLNM-UHFFFAOYSA-N n-cyclopropyl-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NC1CC1 STYBYKUEWSHLNM-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- UEUBEPHODYIOJJ-UHFFFAOYSA-N (2,6-dimethylpyridin-4-yl)methanamine Chemical compound CC1=CC(CN)=CC(C)=N1 UEUBEPHODYIOJJ-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PDJBCEJYPSFMMO-APWZRJJASA-N (2r,3s)-3-(dibenzylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1CN([C@H]([C@@H](C)O)CC)CC1=CC=CC=C1 PDJBCEJYPSFMMO-APWZRJJASA-N 0.000 description 1
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 1
- QNLAYSBIWHHNIT-UHFFFAOYSA-N (3-methylpyridin-2-yl)methanamine Chemical compound CC1=CC=CN=C1CN QNLAYSBIWHHNIT-UHFFFAOYSA-N 0.000 description 1
- DCSKAVJDRSTGDL-UHFFFAOYSA-N (4,6-dimethylpyridin-3-yl)methanamine Chemical compound CC1=CC(C)=C(CN)C=N1 DCSKAVJDRSTGDL-UHFFFAOYSA-N 0.000 description 1
- HXFYXLLVIVSPLT-UHFFFAOYSA-N (6-methylpyridin-2-yl)methanamine Chemical compound CC1=CC=CC(CN)=N1 HXFYXLLVIVSPLT-UHFFFAOYSA-N 0.000 description 1
- NZPFQOXRHLUPRT-UHFFFAOYSA-N (6-methylpyridin-3-yl)methanamine Chemical compound CC1=CC=C(CN)C=N1 NZPFQOXRHLUPRT-UHFFFAOYSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- TYGWOGSLRFKUOH-UHFFFAOYSA-N 1-chloro-2-fluoropurine Chemical compound FC=1N(C=C2N=CN=C2N=1)Cl TYGWOGSLRFKUOH-UHFFFAOYSA-N 0.000 description 1
- KLXJPQNHFFMLIG-UHFFFAOYSA-N 1-ethoxy-2,2,2-trifluoroethanol Chemical compound CCOC(O)C(F)(F)F KLXJPQNHFFMLIG-UHFFFAOYSA-N 0.000 description 1
- QHSMEGADRFZVNE-UHFFFAOYSA-N 1-hydroxymidazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CO)=NC=C2CN=C1C1=CC=CC=C1F QHSMEGADRFZVNE-UHFFFAOYSA-N 0.000 description 1
- WKZVDWLQOBEQLS-UHFFFAOYSA-M 1-methoxy-2,6-dimethylpyridin-1-ium;methyl sulfate Chemical class COS([O-])(=O)=O.CO[N+]1=C(C)C=CC=C1C WKZVDWLQOBEQLS-UHFFFAOYSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JSZOAYXJRCEYSX-UHFFFAOYSA-N 1-nitropropane Chemical compound CCC[N+]([O-])=O JSZOAYXJRCEYSX-UHFFFAOYSA-N 0.000 description 1
- NYZSKEULTVZUAW-UHFFFAOYSA-N 2,2-bis(trifluoromethyl)oxirane Chemical compound FC(F)(F)C1(C(F)(F)F)CO1 NYZSKEULTVZUAW-UHFFFAOYSA-N 0.000 description 1
- LIDGFHXPUOJZMK-UHFFFAOYSA-N 2,6-dimethyl-1-oxidopyridin-1-ium Chemical compound CC1=CC=CC(C)=[N+]1[O-] LIDGFHXPUOJZMK-UHFFFAOYSA-N 0.000 description 1
- AQZRARFZZMGLHL-UHFFFAOYSA-N 2-(trifluoromethyl)oxirane Chemical compound FC(F)(F)C1CO1 AQZRARFZZMGLHL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QEJQCRXSZVXYEO-UHFFFAOYSA-N 2-fluoro-9-propan-2-yl-n-[[6-(trifluoromethyl)pyridin-3-yl]methyl]purin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=C(C(F)(F)F)N=C1 QEJQCRXSZVXYEO-UHFFFAOYSA-N 0.000 description 1
- YIDSLZLYPNKFDM-UHFFFAOYSA-N 2-fluoro-n-(pyridin-3-ylmethyl)-7h-purin-6-amine Chemical compound C=12N=CNC2=NC(F)=NC=1NCC1=CC=CN=C1 YIDSLZLYPNKFDM-UHFFFAOYSA-N 0.000 description 1
- OQMIBSYMIWCEPD-UHFFFAOYSA-N 2-fluoro-n-[(3-fluorophenyl)methyl]-7h-purin-6-amine Chemical compound FC1=CC=CC(CNC=2C=3N=CNC=3N=C(F)N=2)=C1 OQMIBSYMIWCEPD-UHFFFAOYSA-N 0.000 description 1
- NVGNXMYVZDRWKT-UHFFFAOYSA-N 2-fluoro-n-[(3-methylpyridin-2-yl)methyl]-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=NC=CC=C1C NVGNXMYVZDRWKT-UHFFFAOYSA-N 0.000 description 1
- ZBPFWASMZINUGP-UHFFFAOYSA-N 2-fluoro-n-[(6-methylpyridin-2-yl)methyl]-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC(C)=N1 ZBPFWASMZINUGP-UHFFFAOYSA-N 0.000 description 1
- QVZYJSUBGXEBBR-UHFFFAOYSA-N 2-fluoro-n-[(6-methylpyridin-3-yl)methyl]-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=C(C)N=C1 QVZYJSUBGXEBBR-UHFFFAOYSA-N 0.000 description 1
- RISHBQWFBUTROQ-UHFFFAOYSA-N 3-amino-1,1,1-trifluoropropan-2-ol Chemical compound NCC(O)C(F)(F)F RISHBQWFBUTROQ-UHFFFAOYSA-N 0.000 description 1
- OCYMJCILWYHKAU-UHFFFAOYSA-N 4,6-dimethyl-2-oxo-1h-pyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C(O)=N1 OCYMJCILWYHKAU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- SJRHYONYKZIRPM-UHFFFAOYSA-N 4-hydroxytolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(CO)C=C1 SJRHYONYKZIRPM-UHFFFAOYSA-N 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- VFVZUDUUXBFNAJ-UHFFFAOYSA-N 9-(cyclopropylmethyl)-2-fluoro-n-(pyridin-3-ylmethyl)purin-6-amine Chemical compound C=12N=CN(CC3CC3)C2=NC(F)=NC=1NCC1=CC=CN=C1 VFVZUDUUXBFNAJ-UHFFFAOYSA-N 0.000 description 1
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010034798 CDC2 Protein Kinase Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 208000007667 Cytochrome P-450 CYP2C19 Inhibitors Diseases 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 208000005487 Cytochrome P-450 CYP2C9 Inhibitors Diseases 0.000 description 1
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000687968 Homo sapiens Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Proteins 0.000 description 1
- 101001112118 Homo sapiens NADPH-cytochrome P450 reductase Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- OQPLORUDZLXXPD-UHFFFAOYSA-N Hydroxymephenytoin Chemical compound C=1C=C(O)C=CC=1C1(CC)NC(=O)N(C)C1=O OQPLORUDZLXXPD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100024262 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000015602 Septin Human genes 0.000 description 1
- 108050004875 Septin Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XPXVAYGVYBQKDE-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-3-yl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)N=C1 XPXVAYGVYBQKDE-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000023643 hair follicle morphogenesis Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000047583 human POR Human genes 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000012312 microtubule nucleation Effects 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 101150101778 mik1 gene Proteins 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VTLDKMJPSILSGK-UHFFFAOYSA-N n-[(2,6-dimethylpyridin-4-yl)methyl]-2-fluoro-7h-purin-6-amine Chemical compound CC1=NC(C)=CC(CNC=2C=3N=CNC=3N=C(F)N=2)=C1 VTLDKMJPSILSGK-UHFFFAOYSA-N 0.000 description 1
- RVGBDSSVBRRJSQ-UHFFFAOYSA-N n-[(2,6-dimethylpyridin-4-yl)methyl]-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC(C)=NC(C)=C1 RVGBDSSVBRRJSQ-UHFFFAOYSA-N 0.000 description 1
- SZQZJKNWJBRXTO-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC(Cl)=C1 SZQZJKNWJBRXTO-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000005392 polarisation enhancment during attached nucleus testing Methods 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000020273 regulation of microtubule cytoskeleton organization Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GDPKZDNQOFJJKW-UHFFFAOYSA-N tert-butyl n-[(4,6-dimethylpyridin-3-yl)methyl]carbamate Chemical compound CC1=CC(C)=C(CNC(=O)OC(C)(C)C)C=N1 GDPKZDNQOFJJKW-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Description
(I)
R1及びR2は、それぞれ独立に、H、アルキル又はハロアルキルであり、
R3及びR4は、それぞれ独立に、H、アルキル、ハロアルキル又はアリールであり、
R5は、アルキル又はシクロアルキル又はシクロアルキル−アルキルであり、そのそれぞれは、必要に応じて1又は複数のOH基で置換されていてもよく、
R6は、シクロプロピルアミノ、シクロプロピルメチルアミノ、シクロブチルアミノ、シクロブチルメチルアミノ並びに
R7、R8及び各R9は、独立に、H、アルキル又はハロアルキルであり、R7、R8及び各R9の少なくとも1つは、H以外である]。
(II)
R1’、R2’、R3’及びR4’の少なくとも1つはハロアルキルであり、その残りは、それぞれ独立に、H、アルキル又はハロアルキルであり、
R5’は、アルキル又はシクロアルキル又はシクロアルキル−アルキルであり、そのそれぞれは、必要に応じて1又は複数のOH基で置換されていてもよく、
R6’は、シクロプロピルアミノ、シクロプロピルメチルアミノ、シクロブチルアミノ、シクロブチルメチルアミノ並びに
R7’、R8’及び各R9’は、独立に、H、ハロ、アルキル又はハロアルキルである]。
増殖性疾患、
ウイルス性疾患、
脳卒中、
脱毛症、
CNS障害、
神経変性疾患、及び
糖尿病。
(II)
R1’、R2’、R3’、及びR4’の少なくとも1つはハロアルキルであり、その残りは、それぞれ独立に、H、アルキル又はハロアルキルであり、
R5’は、アルキル又はシクロアルキル又はシクロアルキル−アルキルであり、そのそれぞれは、1又は複数のOH基で置換されていてもよく、
R6’は、シクロプロピルアミノ、シクロプロピルメチルアミノ、シクロブチルアミノ、シクロブチルメチルアミノ並びに
R7’、R8’及び各R9’は、独立に、H、ハロ、アルキル又はハロアルキルである)。
本発明の第2の態様は、薬学的に許容される希釈剤、賦形剤若しくは担体、又はこれらの混合物と混合した本発明の化合物を含む医薬組成物に関する。本発明の化合物(その薬学的に許容される塩、エステル及び薬学的に許容される溶媒和物を含めて)は、特にヒトの治療のために、単独で投与することができるが、これらは一般に、医薬担体、賦形剤又は希釈剤と混合して投与される。この医薬組成物は、ヒト用医薬及び獣医薬として、ヒト又は動物に使用することができる。
本発明の化合物は、塩又はエステル、特に、薬学的に許容される塩又はエステルとして存在することができる。
先に論じた本発明のすべての態様では、本発明は、適切な場合、本発明の化合物のすべての鏡像異性体及び互変異性体を含む。当業者は、化合物は、光学的性質(1又は複数の不斉炭素原子)又は互変異性特性を有することを認識する。対応する鏡像異性体及び/又は互変異性体は、当技術分野で既知の方法によって単離/調製することができる。
いくつかの本発明の化合物は、立体異性体及び/又は幾何異性体として存在することができ、例えば、これらは、1又は複数の非対称中心及び/又は幾何的中心を有することができ、したがって、2つ以上の立体異性体及び/又は幾何的形態で存在することができる。本発明は、こうした阻害剤のすべての個々の立体異性体及び幾何異性体、並びにこれらの混合物の使用を意図する。特許請求の範囲で使用される用語は、これらの形態を包含し、但し、前記形態は、適切な機能活性(必ずしも同じ程度ではない)を保持する。
本発明は、本発明の化合物の溶媒和物形態も含む。特許請求の範囲において使用される用語は、これらの形態を包含する。
本発明は、さらに、様々な結晶形態、多形形態及び無水形態又は水和形態における本発明の化合物に関する。化合物は、そのような化合物の合成的調製において使用される溶媒からの精製及び又は単離の方法をわずかに変更することによって、任意のそのような形態で単離することができることが、医薬品産業においてよく確立されている。
本発明は、プロドラッグ形態での本発明の化合物をさらに含む。そのようなプロドラッグは、一般に、1又は複数の適切な基が、ヒト又は哺乳動物の対象に投与されると、修飾が逆に戻ることができるように修飾された、本発明の化合物である。そのような逆戻りは、そのような対象中に自然に存在する酵素によって通常実施されるが、そのようなプロドラッグと一緒に第2の作用剤を投与することによって、逆戻りをインビボで実施することが可能である。そのような修飾の例には、エステル(例えば、任意の上述したもの)が含まれ、逆戻りは、エステラーゼなどによって実施することができる。他のそのような系は、当業者に公知である。
本発明の医薬組成物は、経口、直腸、膣、非経口、筋肉内、腹腔内、動脈内、クモ膜下、気管支内、皮下、皮内、静脈内、経鼻、頬側又は舌下の投与経路に適合させることができる。
当業者は、本組成物の1つの適切な用量を容易に決定することによって、過度の実験を行うことなく、対象に投与することができる。一般に、医師は、個々の患者にとって最適となる実際の投与量を決定し、これは、使用される特定の化合物活性、その化合物の代謝的安定性及び作用の長さ、年齢、体重、全体的な健康、性別、飲食物、投与の様式及び時間、排泄率、薬剤の組合せ、特定の状態の重症度、並びに個々の受けている治療を含めた、様々な要因に依存する。本明細書に開示される投与量は、平均ケースの例示的なものである。個々の場合によって、より多い又はより少ない投与量範囲が適することももちろんあり得るが、そのようなものも本発明の目的の範囲内である。
本発明の化合物は、抗増殖活性を有することが見出されており、したがって、例えば、がん、白血病等の増殖性疾患、又は例えば、乾癬及び再狭窄等の制御されない細胞増殖に関連する他の疾患の治療に使用されると考えられる。
本発明の別の態様は、サイクリン依存性キナーゼ、オーロラキナーゼ、GSK及び/又はPLK酵素の1又は複数の活性に影響する、さらなる候補化合物を同定するためのアッセイにおける、先に定義した化合物の使用に関する。
(i)前記キナーゼの既知の基質の存在下で、リガンドをサイクリン依存性キナーゼ、オーロラキナーゼ、GSK又はPLK酵素と接触させるステップと;
(ii)前記キナーゼと前記既知の基質との相互作用の任意の変化を検出するステップと;
を含み、前記リガンドが本発明の化合物である方法を提供する。
(a)先に説明したアッセイ法を実施するステップと、
(b)リガンド結合ドメインに結合することができる、1又は複数のリガンドを同定するステップと、
(c)一量の前記1又は複数のリガンドを調製するステップと
を含む方法に関する。
(a)先に説明したアッセイ法を実施するステップと、
(b)リガンド結合ドメインに結合することができる、1又は複数のリガンドを同定するステップと、
(c)前記1又は複数のリガンドを含む医薬組成物を調製するステップと
を含む方法を提供する。
(a)先に説明したアッセイ法を実施するステップと、
(b)リガンド結合ドメインに結合することができる、1又は複数のリガンドを同定するステップと、
(c)リガンド結合ドメインに結合することができる、前記1又は複数のリガンドを修飾するステップと、
(d)先に説明したアッセイ法を実施するステップと、
(e)必要に応じて、前記1又は複数のリガンドを含む医薬組成物を調製するステップと
を含む方法を提供する。
化学物質及び溶媒は、市販供給源から購入し、別段の記載のない限り、受け取った状態で使用した。THF及びEt2Oは、N2下でナトリウム−ベンゾフェノンを用いて、還流下で加熱することによって乾燥し、蒸留によって収集した。トルエンは、N2下のナトリウム上で、還流下で加熱することによって乾燥した。CH2Cl2は、N2下のCaH2上で、還流下で加熱することによって乾燥した。使用したマイクロ波発振器は、CEM社製「Discover」モデルであり、環状の単一モード空洞デザインを有しており、これによりマイクロ波照射を試料管に集中させた。TLC(thin-layer chromatography、薄層クロマトグラフィー)は、シリカゲルG60(0.25cm)でコーティングしたガラスプレートを使用して実施した。展開したプレートは、空気で乾燥し、UVランプ(254/365nm)下で分析した。別段の記載のない限り、無水MgSO4を有機溶液の標準的な乾燥剤として使用した。フラッシュカラムクロマトグラフィーは、Fluorochem社製シリカゲル(35〜70μm)を使用して実施した。融点(mp、melting point)は、Electrothermal 9100キャピラリー融点装置を用いて求め、修正していない。略語(dec)は分解点を表す。すべての場合において、1H−NMRスペクトルは、重水素化溶媒をロックとして、及び残留溶媒を内部基準として使用して、Broker Avance 300(300.1MHz)又はVarian Gemini 2000(300MHz)分光計で記録した。PENDANTシーケンス(sequence)を使用する13C−NMRスペクトルは、Bruker Avance 300(75.5MHz)分光計で記録した。すべての他の13C−スペクトルは、合成パルス1Hデカップリングを使用して、Varian Gemini 2000(75.5MHz)分光計で記録した。カップリング定数(J)は、最も近い0.1Hzまで引用する。以下の略語を使用する:s、一重線;d、二重線;t、三重線;q、四重線;qu、五重線(quintuplet);m、多重線及びbr、幅広線。微量元素分析は、Mrs S Williamson、School of Chemistry、Purdie Building、University of St. Andrews、UKによって実施された。得られた結果は計算値の0.4%以内であった。エレクトロスプレー質量スペクトル(ESI、Electrospray mass spectra)は、Waters 2975 HPLCに連結したMicromass社製LCT質量分析計で記録した。分析用RP−HPLCは、Dionex P580ポンプに連結したDionex ASI-100自動試料注入器を使用して実施した。25℃の温度に維持したPhenomenex社製カラム(150×4.60mm、Synergi 4μ hydro-RP 80Å)を分析目的で使用した。HPLCユニットは、Chromeleonソフトウェアを使用して制御した。1mL/分の流速で、H2O/MeCN系(0.1%のCF3COOHを含む)を使用して線形勾配溶出を実施した。純度は、クロマトグラム(λ=254nm)の積分によって評価した。
(2R,3S)−3−アミノ−ペンタン−2−オールは、アミンに使用した保護基が異なる2つの経路の一方又は他方によって調製した。
トリチルを保護基として使用した経路1
(S)−2−(トリチルアミノ)ブタン−1−オール
(S)−2−(ジベンジルアミノ)ブタン−1−オール
合計21の化合物をインビトロ組換えキナーゼアッセイにおいて、及び腫瘍細胞に対して評価し、セリシクリブと比較した。これらのcdk阻害剤のうちの大多数は、セリシクリブより強力であることが判明した。
化合物の細胞効力を求めるために、各化合物の細胞毒性をH460非小細胞肺癌(NSCLC、non-small cell lung cancer)細胞株に対して求めた。標準的な細胞毒性法を以下の通り実施した。H460細胞を96ウェルプレート中の10%のFCSを含むRPMI培地中に、その倍加時間にとって適切な量で播種し(1ウェル当たり3000細胞)、37℃、5%のCO2で一晩インキュベートした。培地を取り出し、漸増濃度の適切な化合物を含む100μlの新鮮な培地を添加し、細胞を37℃、5%のCO2で72時間インキュベートした。アラマーブルー(Roche社製、Lewes、United Kingdom)の10%原料を培地中に調製し、100μlを細胞に添加し、これを2時間インキュベートした。吸光度は、544〜595nmで、Wallac Victor 2 1420マルチラベルカウンターで測定した。3つの独立した実験の平均を表3に示す。
セリシクリブは、転写に対するその作用を介してアポトーシスを誘発することが以前に示されている。したがって、セリシクリブは、転写の開始及び伸長に必要とされる、RNAポリメラーゼIIのリン酸化に関与する、CDK7及びCDK9を阻害する。転写が阻害される結果として、Mcl−1などの短い半減期を有するいくつかのタンパク質のレベルは減少し、それによってアポトーシスを誘発する。
目的
CYP特異的基質の代謝の分析によって、化合物[1]が、5つのCYPアイソフォームの活性を阻害するかどうかを識別すること。以下に示す従来技術化合物である[A1]、[A2]及び[A3]を使用して、比較研究を実施した。
[A1] [A2] [A3]
化合物[A1]、[A2]及び[A3]は、国際公開第2004/016612号パンフレット(Cyclacel Limited)に示されている方法に従って合成した。
6つの濃度の試験化合物(DMSO中0.05、0.25、0.5、2.5、5、25μM;最終DMSO濃度=0.35%)をプローブ基質エトキシレゾルフィン(0.5μM)の存在下で、ヒト肝ミクロソーム(0.25mg/mL)及びNADPH(1mM)とともに、37℃で5分間インキュベートした。選択的CYP1A阻害剤であるα−ナフトフラボンを陽性対照として試験化合物と一緒にスクリーニングした。
6つの濃度の試験化合物(DMSO中0.05、0.25、0.5、2.5、5、25μM;最終DMSO濃度=0.25%)をプローブ基質トルブタミド(120μM)の存在下で、ヒト肝ミクロソーム(1mg/mL)及びNADPH(1mM)とともに、37℃で60分間インキュベートした。選択的CYP2C9阻害剤であるスルファフェナゾールを陽性対照として試験化合物と一緒にスクリーニングした。
6つの濃度の試験化合物(DMSO中0.05、0.25、0.5、2.5、5、25μM;最終DMSO濃度=0.25%)をプローブ基質メフェニトイン(25μM)の存在下で、ヒト肝ミクロソーム(0.5mg/mL)及びNADPH(1mM)とともに、37℃で60分間インキュベートした。選択的CYP2C19阻害剤であるトラニルシプロミンを陽性対照として試験化合物と一緒にスクリーニングした。
6つの濃度の試験化合物(DMSO中0.05、0.25、0.5、2.5、5、25μM;最終DMSO濃度=0.25%)をプローブ基質デキストロメトルファン(5μM)の存在下で、ヒト肝ミクロソーム(0.5mg/mL)及びNADPH(1mM)とともに、37℃で30分間インキュベートした。選択的CYP2D6阻害剤であるキニジンを陽性対照として試験化合物と一緒にスクリーニングした。
6つの濃度の試験化合物(DMSO中0.05、0.25、0.5、2.5、5、25μM;最終DMSO濃度=0.26%)をプローブ基質ミダゾラム(2.5μM)の存在下で、ヒト肝ミクロソーム(0.25mg/mL)及びNADPH(1mM)とともに、37℃で5分間インキュベートした。選択的CYP3A4阻害剤であるケトコナゾールを陽性対照として試験化合物と一緒にスクリーニングした。
5つのCYPアイソフォームに対する各化合物についてのIC50(μM)を表5に示す。
目的
主要なチトクロムP450アイソフォームのうちのどれが4つの試験化合物の代謝に関与するかを識別すること。
ヒトNADPHチトクロムP450還元酵素と同時発現した、cDNA発現ヒトCYP450酵素調製物(Bactosomes(商標))は、Cypex Ltdによって供給された。Bactosomes(商標)(最終のP450濃度CYP1A2 100pmol/mL、CYP2C8 50pmol/mL、CYP2C9 25pmol/mL、CYP2C19 100pmol/mL、CYP2D6 50pmol/mL及びCYP3A4 25pmol/mL)、pH7.4の0.1Mのリン酸緩衝液並びに試験化合物(最終基質濃度=5μM;最終DMSO濃度=0.25%)を37℃でプレインキュベートした後、NADPH(最終濃度=1mM)を添加することによって反応を開始した。インキュベーションはまた、対照のバクトソーム(bactosome)(P450酵素がまったく存在しない)を使用しても実施することによって、任意の非酵素的分解を明らかにした。最終インキュベーション体積は25μLであった。各CYP450アイソフォームによって特異的に代謝されることが知られている化合物を対照化合物として使用した。
ピーク面積比の自然対数(対照のバクトソームを用いて、インキュベーション中の任意の損失を補正した)を時間に対してプロットし、線の傾きを求めた。
6つのCYPのそれぞれの存在下での、各化合物についての半減期(分)を表6に示す。
化合物のインビトロでのキナーゼ効力を評価するために、これらをCDK2及びCDK9に対してスクリーニングした。キナーゼアッセイは、Cyclacel. Ltd、Dundee、UKで作製された、組換えCDK/サイクリンを使用して、96ウェルプレート中で実施した。CDK2及びCDK9アッセイは、25μlの全体積で、アッセイ緩衝液(25mMのb−グリセロホスフェート、20mMのMOPS、5mMのEGTA、1mMのDTT及び1mMのNaVO3、pH7.4)中で実施し、この中に、適切な基質(CDK2/サイクリンE及びCDK2/サイクリンAに対して精製ヒストンH1、CDK9/サイクリンT1に対してビオチニル−Ahx−(YSPTSPS)4)を含む、2〜4μgの活性酵素を添加した。反応は、Mg/ATP混合物(15mMのMgCl2+1ウェル当たり30〜50kBqの[−32P]−ATPを含む、100μMのATP)を添加することによって開始し、必要に応じて、30℃で、混合物を15分間(CDK2/サイクリンE)、30分間(CDK2/サイクリンA)又は45分間(CDK9/サイクリンT1)インキュベートした。CDK2の反応は、25μlの75mMのリン酸を添加することによって停止し、その後にP81濾板(Whatman Polyfiltronics、Kent、UK)を通して濾過した。CDK9については、CDK2アッセイのように、反応は、25μlの75mMのリン酸を添加することによって停止し、次いで各ウェルに5μlの10mg/mlのアビジンを添加し、さらに2分間インキュベートし、その後に濾過した。75mMのオルトリン酸で3回洗浄した後、プレートを乾燥し、シンチラントを添加し、組み込まれた放射能をシンチレーションカウンター(TopCount、Packard Instruments、Pangbourne、Berks、UK)で測定した。キナーゼアッセイのための化合物は、DMSO中の10mMの原料として作製し、アッセイ緩衝液中の10%のDMSOに希釈した。曲線−フィッティングソフトウェア(XLfit 4.00版、ID Business Solutions Ltd、Guildford、Surrey、UK)を使用してデータを分析することによって、IC50(キナーゼ活性を50%阻害する、化合物の濃度)を求めた。2つの点の平均は、表6と8に見ることができる。
表7中の結果は、従来技術の化合物[A3]及び化合物[1]は、最も強力なキナーゼ阻害剤であることを示す。
化合物の細胞効力を判定するために、各化合物の細胞毒性を様々な細胞株に対して求めた。標準的な細胞毒性法を以下の通り実施した。細胞を96ウェルプレート中の10%のFCSを含む、RPMI又はDMEM培地中に、その倍加時間にとって適切な量で播種し(1ウェル当たり2〜5000細胞)、37℃、5%のCO2で一晩インキュベートした。培地を取り出し、漸増濃度の適切な化合物を含む100μlの新鮮な培地を添加し、細胞を37℃、5%のCO2で72時間インキュベートした。アラマーブルー(Roche社製、Lewes、United Kingdom)の10%原料を培地中に調製し、100μlを細胞に添加し、これを2時間インキュベートした。吸光度は、544〜595nmで、Wallac Victor 2 1420マルチラベルカウンターで測定した。
21の細胞株に対する、細胞の細胞毒性分析結果を表8に示す。化合物[1]は、従来技術の化合物[A1]、[A2]又は[A3]よりも、著しくより強力である。
Claims (45)
- 式(I)の化合物又は薬学的に許容されるその塩
[式中、
R1及びR2は、それぞれ独立に、H、アルキル又はハロアルキルであり、
R3及びR4は、それぞれ独立に、H、アルキル、ハロアルキル又はアリールであり、
R5は、アルキル又はシクロアルキル又はシクロアルキル−アルキルであり、そのそれぞれは、必要に応じて1又は複数のOH基で置換されていてもよく、
R6は、
R7、R8及び各R9は、独立に、H、アルキル又はハロアルキルであり、R7、R8及び各R9の少なくとも1つは、H以外である]。 - R1及びR2の一方がHであり、他方がアルキルである、請求項1に記載の化合物。
- R1及びR2の一方がHであり、他方がメチル、エチル又はイソプロピルである、請求項1又は2に記載の化合物。
- R1がエチルであり、R2がHである、請求項1〜3のいずれかに記載の化合物。
- R3及びR4が、それぞれ独立に、H、アルキル、ハロアルキル又はアリールであり、R3及びR4の少なくとも1つがH以外である、請求項1〜4のいずれかに記載の化合物。
- R3及びR4の一方がHであり、他方がアルキル又はハロアルキルである、請求項1〜5のいずれかに記載の化合物。
- R3がHであり、R4がアルキル又はハロアルキルである、請求項1〜6のいずれかに記載の化合物。
- R3がHであり、R4がメチルである、請求項1〜7のいずれかに記載の化合物。
- YがNである、請求項1〜8のいずれかに記載の化合物。
- XがCHであり、ZがC−Meであり、R7がHであり、R8がMeである、請求項9に記載の化合物。
- XがCHであり、ZがC−Meであり、R7及びR8がともにHである、請求項9に記載の化合物。
- XがCHであり、ZがC−CF3であり、R7及びR8がともにHである、請求項9に記載の化合物。
- XがNである、請求項1〜8のいずれかに記載の化合物。
- YがC−Meであり、ZがCHであり、R7及びR8がともにHである、請求項13に記載の化合物。
- Y及びZがCHであり、R7がHであり、R8がMeである、請求項13に記載の化合物。
- ZがNである、請求項1〜8のいずれかに記載の化合物。
- XがCHであり、YがC−Meであり、R7がMeであり、R8がHである、請求項16に記載の化合物。
- R5がイソプロピルである、請求項1〜17のいずれかに記載の化合物。
- 以下のものから選択される、請求項1〜18のいずれかに記載の化合物。
- 式IIの化合物、又は薬学的に許容されるその塩
[式中、
R1’、R2’、R3’及びR4’の少なくとも1つはハロアルキルであり、その残りは、それぞれ独立に、H、アルキル又はハロアルキルであり、
R5’は、アルキル又はシクロアルキル又はシクロアルキル−アルキルであり、そのそれぞれは、必要に応じて1又は複数のOH基で置換されていてもよく、
R6’は、
R7’、R8’及び各R9’は、独立に、H、ハロ、アルキル又はハロアルキルである]。 - R5’がイソプロピルである、請求項20に記載の化合物。
- Y’がNであり、X’及びZ’がCHであり、R7’及びR8’がともにHである、請求項20又は21に記載の化合物。
- R1’及びR2’の一方がHであり、他方がアルキルであり、又はR1’及びR2’がともにHである、請求項20〜22のいずれかに記載の化合物。
- R3’及びR4’の一方がHであり、他方がCF3である、請求項20〜23のいずれかに記載の化合物。
- 以下のものから選択される化合物。
- 以下のものから選択される化合物。
- 化合物(2R,3S−3−(6−((4,6−ジメチルピリジン−3−イルメチルアミノ)−9−イソプロピル−9H−プリン−2−イルアミノ)ペンタン−2−オール、又は薬学的に許容されるその塩若しくはエステル。
- 薬学的に許容される希釈剤、賦形剤若しくは担体、又はこれらの混合物と混合されている、請求項1〜27のいずれかに記載の化合物を含む医薬組成物。
- 増殖性疾患を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- 増殖性疾患ががん又は白血病である、請求項29に記載の使用。
- 増殖性疾患が、糸球体腎炎、関節リウマチ、乾癬又は慢性閉塞性肺疾患である、請求項29に記載の使用。
- ウイルス性疾患を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- ウイルス性疾患が、ヒトサイトメガロウイルス(HCMV)、単純ヘルペスウイルス1型(HSV−1)、ヒト免疫不全ウイルス1型(HIV−1)、及び水痘帯状疱疹ウイルス(VZV)から選択される、請求項32に記載の使用。
- CNS障害を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- CNS障害が、アルツハイマー病又は双極性障害である、請求項34に記載の使用。
- 脱毛症を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- 脳卒中を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- 糖尿病を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- 糖尿病がII型糖尿病である、請求項38に記載の使用。
- 神経変性疾患を治療するための薬物の調製における、請求項1〜27のいずれかに記載の化合物の使用。
- 神経変性疾患がニューロンアポトーシスである、請求項40に記載の使用。
- サイクリン依存性キナーゼ、オーロラキナーゼ、GSK及びPLK酵素の1又は複数を阻害することができる、さらなる候補化合物を同定するためのアッセイにおける、請求項1〜27のいずれかに記載の化合物の使用(ただし、ヒトを対象としたアッセイを除く)。
- アッセイが競合的結合アッセイである、請求項42に記載の使用(ただし、ヒトを対象としたアッセイを除く)。
- 医薬に含有させて使用するための、請求項1〜27のいずれかに記載の化合物。
- 増殖性疾患、ウイルス性疾患、神経変性疾患、CNS障害、糖尿病、脱毛症及び脳卒中から選択される疾患を治療するための、請求項1〜27のいずれかに記載の化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92189707P | 2007-04-04 | 2007-04-04 | |
GB0706632.7 | 2007-04-04 | ||
US60/921,897 | 2007-04-04 | ||
GBGB0706632.7A GB0706632D0 (en) | 2007-04-04 | 2007-04-04 | New purine derivatives |
PCT/GB2008/001173 WO2008122767A2 (en) | 2007-04-04 | 2008-04-02 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010523534A JP2010523534A (ja) | 2010-07-15 |
JP2010523534A5 JP2010523534A5 (ja) | 2011-04-21 |
JP5466145B2 true JP5466145B2 (ja) | 2014-04-09 |
Family
ID=38090893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010501585A Active JP5466145B2 (ja) | 2007-04-04 | 2008-04-02 | 抗増殖性を有する2,6,9−置換プリン誘導体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8592581B2 (ja) |
EP (1) | EP2139893B1 (ja) |
JP (1) | JP5466145B2 (ja) |
CN (1) | CN101679434B (ja) |
AU (1) | AU2008235361B2 (ja) |
BR (1) | BRPI0809996B8 (ja) |
CA (1) | CA2681529C (ja) |
ES (1) | ES2427845T3 (ja) |
GB (1) | GB0706632D0 (ja) |
HK (1) | HK1139939A1 (ja) |
MX (1) | MX2009010660A (ja) |
PL (1) | PL2139893T3 (ja) |
RU (1) | RU2461559C2 (ja) |
WO (1) | WO2008122767A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
GB0903346D0 (en) | 2009-02-27 | 2009-04-08 | Cambridge Advanced Tech | Transgenic Plants |
GB201001075D0 (en) * | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
DK3244891T3 (da) | 2015-01-16 | 2022-10-24 | Massachusetts Gen Hospital | Forbindelser til forbedring af mrna-splejsning |
JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Hp1の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
US10927113B2 (en) | 2017-01-26 | 2021-02-23 | Cyclacel Limited | Process for preparing purine derivatives |
EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
GB202000901D0 (en) | 2020-01-22 | 2020-03-04 | Cyclacel Ltd | Process |
WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
RU2001124352A (ru) * | 1999-02-01 | 2004-02-20 | Си Ви Терапьютикс, Инк. (Us) | Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа |
US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
WO2003002565A1 (en) * | 2001-06-27 | 2003-01-09 | Cyclacel Limited | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
ATE433967T1 (de) * | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
MX2007002169A (es) * | 2004-08-27 | 2007-08-14 | Cyclacel Ltd | Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes. |
GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
-
2007
- 2007-04-04 GB GBGB0706632.7A patent/GB0706632D0/en not_active Ceased
-
2008
- 2008-04-02 CN CN2008800189406A patent/CN101679434B/zh active Active
- 2008-04-02 AU AU2008235361A patent/AU2008235361B2/en active Active
- 2008-04-02 BR BRPI0809996A patent/BRPI0809996B8/pt active IP Right Grant
- 2008-04-02 WO PCT/GB2008/001173 patent/WO2008122767A2/en active Application Filing
- 2008-04-02 ES ES08718980T patent/ES2427845T3/es active Active
- 2008-04-02 JP JP2010501585A patent/JP5466145B2/ja active Active
- 2008-04-02 EP EP08718980.9A patent/EP2139893B1/en active Active
- 2008-04-02 RU RU2009140753/04A patent/RU2461559C2/ru active
- 2008-04-02 MX MX2009010660A patent/MX2009010660A/es active IP Right Grant
- 2008-04-02 PL PL08718980T patent/PL2139893T3/pl unknown
- 2008-04-02 CA CA2681529A patent/CA2681529C/en active Active
-
2009
- 2009-10-05 US US12/573,337 patent/US8592581B2/en active Active
-
2010
- 2010-07-06 HK HK10106563.2A patent/HK1139939A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008122767A3 (en) | 2008-12-31 |
JP2010523534A (ja) | 2010-07-15 |
US8592581B2 (en) | 2013-11-26 |
MX2009010660A (es) | 2010-02-17 |
AU2008235361A1 (en) | 2008-10-16 |
HK1139939A1 (en) | 2010-09-30 |
RU2009140753A (ru) | 2011-05-10 |
BRPI0809996B1 (pt) | 2019-09-03 |
CA2681529C (en) | 2015-06-30 |
WO2008122767A2 (en) | 2008-10-16 |
CN101679434B (zh) | 2013-09-25 |
ES2427845T3 (es) | 2013-11-04 |
BRPI0809996B8 (pt) | 2021-05-25 |
BRPI0809996A2 (pt) | 2014-10-14 |
EP2139893B1 (en) | 2013-06-19 |
AU2008235361B2 (en) | 2013-02-14 |
RU2461559C2 (ru) | 2012-09-20 |
US20100093769A1 (en) | 2010-04-15 |
GB0706632D0 (en) | 2007-05-16 |
PL2139893T3 (pl) | 2013-11-29 |
EP2139893A2 (en) | 2010-01-06 |
CN101679434A (zh) | 2010-03-24 |
CA2681529A1 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5466145B2 (ja) | 抗増殖性を有する2,6,9−置換プリン誘導体 | |
EP1641805B1 (en) | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | |
AU2004264419B2 (en) | 6-substituted anilino purines as RTK inhibitors | |
JP4723858B2 (ja) | 新しいプリン誘導体 | |
RU2478100C2 (ru) | Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы | |
US7544689B2 (en) | Purine derivatives | |
US20090215805A1 (en) | 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110302 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110302 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130708 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131009 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131209 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5466145 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |